Transcription of The Stock Network Interview with Tetratherix (ASX:TTX), CEO Will Knox
Lel Smits: Tetratherix is progressing a portfolio of regenerative medicine technologies built on its proprietary Tetra Matrix platform, designed to support bone regeneration, tissue spacing, and tissue healing across multiple surgical applications. With several products moving through clinical validation and regulatory pathways, Tetratherix is approaching an important transition from a research-focused organisation toward commercial scale. Key developments include global dental distribution progress, advancing FDA pathways across multiple programs, and new partnerships with leading medical technology companies.
I’m joined today by Will Knox to discuss the company’s development milestones, the strategy behind its multiple product platform, and what the next phase of growth could look like as Tetratherix moves towards commercialisation. Will, welcome to the Stock Network.
Will Knox: Thanks, great to be here.
Lel Smits: Tetratherix is developing a pipeline of products across bone regeneration, tissue spacing, and tissue healing using its Tetramatrix™ technology platform. Will, how are you using this diversified platform to create multiple commercial pathways for the company?
Will Knox: Well, the underlying technology that this whole opportunity set is built upon is a polymer synthetic platform called Tetra Matrix. And the beauty of Tetramatrix™ is that the polymer itself can be used across a range of different applications in parallel.
And part of the reason for that is because the synthetic polymer that is actually underpinning the technology itself changes purely on concentration, so the amount of polymer that you mix with water. And then the end result provides a whole range of different physical and chemical applications that we can use for a differentiated indication set in clinical settings around the world.
Lel Smits: Excellent. And Tetratherix has secured a global dental partnership with Henry Shine, while also advancing several FDA regulatory pathways across its pipeline, including products that are designed for orthopaedics, prostate cancer treatment, also cataract surgery. How did these partnerships and regulatory milestones help to position Tetratherix for its transition from research and development to commercial growth?
Will Knox: Well, again, the platform nature of the material that we’re bringing to market allows us to have very field-specific relationships or partnerships with market leaders all around the world. And so Henry Shine is a really good example of one of those, where they will be taking the technology that we’ve spent years developing through our R&D pathways and then commercialising that through their extensive and established sales and marketing infrastructure in all markets around the world.
And so the whole commercial model for Tetratherix is built upon the ability for us to hand off the final commercialisation and the sales and marketing work that’s required to bring these technologies to market. And a lot of that’s built on the many decades of experience that we’ve got in the market and the expensive and arduous work that’s involved with setting up and establishing these sales and marketing infrastructures. So we don’t need to do any of that.
We don’t need to pay for it. But importantly, what this means is that the technology and its capabilities are recognised by market leaders like Henry Shine, with more announcements to come about who we’ll be partnering with with the technologies across the platform.
Lel Smits: Brilliant. And while we’re talking about commercialisation and scale, you’ve emphasised a lean operating model, tightly managed capital, while also progressing multiple clinical and regulatory programs globally. As you really are approaching the next phase where several products could now move towards commercialisation, how do you plan to scale efficiently while also continuing to invest in innovation?
Will Knox: Well, because of the platform nature of the material, it allows us to manufacture multiple applications in the same manufacturing capability here in Sydney, Australia. We’re very proud exporters of advanced manufacturing tech based out of Sydney to global markets around the world.
And so our manufacturing capability that we’ve spent many years establishing enables us to vertically integrate a lot of the different manufacturing capabilities of the process, meaning that the pod system or the modular system that we have in the business allows us to more cost effectively increase the infrastructure that we require over the years to come. But maintaining, of course, which we want to make sure we do in the business, a spend of roughly 35 to 40 percent of our general operating expenditure into R&D, because importantly, the platform of products that we’re bringing to market now is not what we’ll always have. We have a really large and expanding pipeline of product applications coming behind it, which we’re very excited to bring to market.
Lel Smits: There certainly is a lot of excitement ahead. Thank you for introducing Tetratherix to us today and look forward to hearing more as that news flow comes through.
Will Knox: Thanks, Lel.
Ends